Sorafenib as Effective, Safe in Elderly RCC Patients as in Younger Ones

PFS, tumor response, and safety outcomes were similar in patient cohorts under age 75 vs those 75 years of age and older.

Source: CancerNetwork - July 16, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news